AbbVie Inc  

(Public, NYSE:ABBV)   Watch this stock  
54.05
+0.05 (0.09%)
After Hours: 54.09 +0.04 (0.08%)
Jul 22, 5:38PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 53.75 - 54.38
52 week 42.25 - 58.27
Open 53.82
Vol / Avg. 14.72M/10.75M
Mkt cap 86.05B
P/E 21.00
Div/yield 0.42/3.11
EPS 2.57
Shares 1.59B
Beta     -
Inst. own 80%
Jul 22, 2014
Q2 2014 AbbVie Inc Earnings Release (Estimated)
Jul 18, 2014
AbbVie Inc To Discuss The Recommended Combination With Shire Plc - Webcast
Jun 25, 2014
AbbVie Conference Call to Discuss Possible Combination with Shire plc
Jun 11, 2014
AbbVie Inc at Goldman Sachs Healthcare Conference
Jun 4, 2014
AbbVie Inc at Jefferies Global Healthcare Conference - Webcast
May 21, 2014
AbbVie Inc at UBS Global Healthcare Conference - Webcast
May 15, 2014
AbbVie Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
May 9, 2014
AbbVie Inc Annual Meeting of the Stockholders
Apr 25, 2014
Q1 2014 AbbVie Inc Earnings Release
Apr 25, 2014
Q1 2014 AbbVie Inc Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 21.48% 21.97%
Operating margin 29.61% 30.14%
EBITD margin - 36.59%
Return on average assets 13.59% 14.69%
Return on average equity 85.55% 105.11%
Employees 25,000 -
CDP Score - -

Address

1 N Waukegan Rd
NORTH CHICAGO, IL 60064-1802
United States - Map
+1-847-9327900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products. AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

Officers and directors

Richard A. Gonzalez Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
William J. Chase Chief Financial Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
Michael Severino M.D. Executive Vice President - Research & Development, Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Laura J. Schumacher Executive Vice President - Business Development, External Affairs, General Counsel
Age: 50
Bio & Compensation  - Reuters
Carlos Alban Executive Vice President - Commercial Operations
Age: 51
Bio & Compensation  - Reuters
Timothy J. Richmond Senior Vice President - Human Resources
Age: 47
Bio & Compensation  - Reuters
Azita Saleki-Gerhardt Ph.D. Senior Vice President - Operations
Age: 50
Bio & Compensation  - Reuters
Thomas A. Hurwich Vice President, Controller
Age: 53
Bio & Compensation  - Reuters
Robert J. Alpern M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Roxanne S. Austin Independent Director
Age: 53
Bio & Compensation  - Reuters